Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 4
2009 2
2010 2
2011 2
2012 8
2013 5
2014 17
2015 16
2016 11
2017 8
2018 8
2019 15
2020 18
2021 13
2022 16
2023 15
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G, Stellato M, Guadalupi V, Sepe P, Claps M, Giannatempo P, Bottiglieri A, Rametta A, Taglialatela I, Vela C, Procopio G, Verzoni E. Fotia G, et al. Among authors: verzoni e. Curr Oncol Rep. 2023 Jun;25(6):671-677. doi: 10.1007/s11912-023-01395-4. Epub 2023 Mar 31. Curr Oncol Rep. 2023. PMID: 37000341 Review.
Immunotherapy advances in uro-genital malignancies.
Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. Ratta R, et al. Among authors: verzoni e. Crit Rev Oncol Hematol. 2016 Sep;105:52-64. doi: 10.1016/j.critrevonc.2016.06.012. Epub 2016 Jun 17. Crit Rev Oncol Hematol. 2016. PMID: 27372200 Review.
Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, Verzoni E, Giannatempo P, Baciarello G, de Braud F, Procopio G. Ottini A, et al. Among authors: verzoni e. Per Med. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7. Per Med. 2022. PMID: 34873959 Review.
Current Understanding of Urachal Adenocarcinoma and Management Strategy.
Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, Mennitto R, de Braud FGM, Verzoni E, Procopio G. Claps M, et al. Among authors: verzoni e. Curr Oncol Rep. 2020 Jan 27;22(1):9. doi: 10.1007/s11912-020-0878-z. Curr Oncol Rep. 2020. PMID: 31989430 Review.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G, Claps M, Pircher C, Porcu L, Sepe P, Guadalupi V, De Giorgi U, Bimbatti D, Nolè F, Carrozza F, Buti S, Iacovelli R, Ciccarese C, Masini C, Baldessari C, Doni L, Cusmai A, Gernone A, Scagliarini S, Pignata S, de Braud F, Verzoni E. Procopio G, et al. Among authors: verzoni e. Tumori. 2023 Feb;109(1):129-137. doi: 10.1177/03008916221138881. Epub 2022 Nov 29. Tumori. 2023. PMID: 36447337 Free PMC article. Clinical Trial.
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis-Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. Grimm MO, et al. Among authors: verzoni e. Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16. Eur Urol. 2024. PMID: 37852850 Free article. Clinical Trial.
Multimodal treatment of advanced renal cancer in 2017.
Mennitto A, Verzoni E, Grassi P, Ratta R, Fucà G, Procopio G. Mennitto A, et al. Among authors: verzoni e. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1395-1402. doi: 10.1080/17512433.2017.1386552. Epub 2017 Oct 6. Expert Rev Clin Pharmacol. 2017. PMID: 28956645 Review.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
151 results